Viral myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis?
Cardiotropic virus infection of mice typically produces florid myocardial inflammation and, in certain strains, elicits a chronic postinfectious autoimmune myocarditis. In humans, myocarditis may progress into cardiomyopathy manifested by interstitial fibrosis and myocyte hypertrophy in the absence of myocardial inflammation. Because of their pleiotropic effects, cytokines may provide a common link between connective tissue changes, myocardial injury, and cardiac autoimmunity. To explore such possibilities, histopathological and serological studies were performed on virus-infected mice which were or were not subject to cytokine manipulation. Mice infected with low doses of encephalomyocarditis virus exhibited little myocardial inflammation although myocyte hypertrophy and reactive fibrosis were common. Profound ultrastructural changes in the interstitium were observed through much of the noninflamed myocardium. B10.A mice which are resistant to the development of postinfectious autoimmune myocarditis developed severe autoimmune myocarditis when infected with Coxsackie virus B3 (CB3) and treated with bacterial lipopolysaccharide (LPS), tumor necrosis factor (TNF), or interleukin 1 (IL-1). B10.A mice given CB3, LPS, TNF, or IL-1 alone did not develop myocarditis and there was no evidence of autoimmune recognition of the heart. When CB3-infected A/J mice, which typically develop autoimmune sequelae to the infection, were treated with an IL-1 receptor antagonist, myocardial injury was diminished and heart antibody activity was reduced. These results suggest that TNF, IL-1, and possibly other cytokines contribute to myocardial pathogenesis and the induction of heart-specific autoimmunity. Further studies may lead to the development of cytokine-based therapeutic approaches to treating myocarditis and cardiomyopathy.
Johns Hopkins University, School of Hygiene and Public Health, Department of Immunology and Infectious Diseases, Baltimore, Maryland 21205.
D A
DA
Neumann
J R
JR
Lane
G S
GS
Allen
A
A
Herskowitz
N R
NR
Rose
D000818:Animals; D009202:Cardiomyopathies / Q000209:etiology* / Q000473:pathology; D003384:Coxsackievirus Infections / Q000150:complications* / Q000473:pathology; D004686:Encephalomyocarditis virus / Q000472:pathogenicity*; D029822:Enterovirus B, Human / Q000472:pathogenicity; D004769:Enterovirus Infections / Q000150:complications* / Q000473:pathology; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009205:Myocarditis / Q000150:complications* / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D012795:Sialoglycoproteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
C507763:IL1RN protein, human; C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D008070:Lipopolysaccharides; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha